From: Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin
Gene name (symbol) | Function | Fold Increase (MO) | Fold Increase (ME-26) | ||
---|---|---|---|---|---|
 |  | -UO126 | +UO126 20 μM | -UO126 | +UO126 20 μM |
B-cell CLL/Lymphoma (BCL2)* | Drug Resistance | 213.65 | 127.7§ | 28.92 | 14.57§ |
V-fos FBJ murine osteosarcoma viral oncogene homolog (FOS)* | Transcription Factor | 26.52 | 2.28§ | 33.85 | 20.59§ |
Met protooncogene (MET) | Growth Factor Receptor | 25.45 | 28.09 | 27.60 | 25.42 |
ATP-binding cassette (MDR/TAP) (ABCB1) | Drug Resistance | 13.6 | 4.66 | Â | Â |
Estrogen receptor 1 (ESR1) | Hormone Receptors | 11.03 | 10.90 | Â | Â |
Breast cancer 1, early onset (BRCA1) | DNA Repair | 6.66 | 1.42‡,§ | 6.68 | 2.88§ |
Androgen receptor (AR) | Hromone Receptors | 6.35 | 10.25§ |  |  |
Estrogen receptor 2 (ESR2) | Hormone Receptor | 4.19 | 10.48§ | 4.53 | 6.15 |
Breast cancer 2, early onset (BRCA2) | DNA Repair | 3.98 | 2.21 | 5.18 | 2.64§ |
Cyclin-dependent kinase inhibitor 2D (CDKN2D) | Cell Cycle | 3.68‡ | 4.88 |  |  |
Cytochrome P450 (CYP3A4) | Drug Metabolism |  |  | 77.12 | 25.06§ |
Peroxisome proliferative activated receptor, gamma (PPARγ) | Hormone Receptor |  |  | 9.72 | 4.55§ |
Tumor protein 53 (TP53) | Drug Resistance | Â | Â | 4.35 | 4.52 |
ATP-binding cassette (ABCC3) | Drug Resistance |  |  | 4.56 | 2.26§ |
*Validation by qRT-PCR | Â | Â | Â | Â | Â |
Gene name (symbol) | Function | Validation (MO) | Validation (ME-26) | ||
 |  | -UO126 | +UO126 | -UO126 20 μM | +UO126 20 μM |
B-cell CLL/Lymphoma (BCL2) | Drug Resistance | 550 | 476 | 123 | 31 |
V-fos FBJ murine osteosacroma viral oncogene homolog (FOS) | Transcription Factor | 16 | 2.14 | 23.88 | 8.9 |